<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87319">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01868451</url>
  </required_header>
  <id_info>
    <org_study_id>13-034</org_study_id>
    <nct_id>NCT01868451</nct_id>
  </id_info>
  <brief_title>Brentuximab Vedotin Combined With AVD Chemotherapy and 30 Gray Involved-Site Radiotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma</brief_title>
  <official_title>A Pilot Study of Brentuximab Vedotin Combined With AVD Chemotherapy and 30 Gray Involved-Site Radiotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan-Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan-Kettering Cancer Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether BV with AVD chemotherapy and radiation is a
      safe and effective treatment. It is hoped that this treatment will improve the ability to
      cure more patients with HL.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>development of significant pulmonary toxicity</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>specifically non-infectious pneumonitis The definition of unacceptable pulmonary toxicity will be defined as the development of grade 2 or higher pneumonitis as defined by Common Terminology Criteria for Adverse Events (CTCAE version 4).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression free survival (PFS) will be calculated from the time of initiation of brentuximab vedotin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the prognostic significance</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>(i.e. correlation with progression free survival) of interim fluorodeoxyglucose-positron emission tomography (PET) in this patient population measured by visual analysis and semi-quantitative analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the prognostic significance of gene-expression based predictor</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>using NanoString technology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the prognostic significance of gene-expression of plasma Epstein Barr virus DNA (EBV-DNA)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>by quantitative PCR,</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Pts with Hodgkin Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 4 cycles of brentuximab vedotin and AVD chemotherapy. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 and 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, and Dacarbazine 375 mg/m2 will be administered on days 1 and 15 of each 28 day cycle. This may be followed by 30 Gy involved site radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brentuximab vedotin (SGN-35)</intervention_name>
    <arm_group_label>Pts with Hodgkin Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin HCL</intervention_name>
    <arm_group_label>Pts with Hodgkin Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinblastine Sulfate</intervention_name>
    <arm_group_label>Pts with Hodgkin Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <arm_group_label>Pts with Hodgkin Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Involved-Site Radiation Therapy (ISRT)</intervention_name>
    <arm_group_label>Pts with Hodgkin Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Interim PET</intervention_name>
    <arm_group_label>Pts with Hodgkin Lymphoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic diagnosis of classical, CD30 positive Hodgkin lymphoma confirmed at
             enrolling institution

          -  FDG-avid disease by FDG-PET/CT and measurable disease of at least 1.5 cm by CT

          -  Ann Arbor Stage I or II disease

          -  At least one of the following unfavorable risk factors as defined by GHSG: bulky
             mediastinal mass (≥one-third maximum transverse thoracic diameter on
             Posterior-Anterior/Lateral Chest X-ray or ≥10cm by CT imaging in axial plane), ESR ≥
             50mm/h or ESR ≥30 mm/h in patients with &quot;B&quot; symptoms, extranodal involvement, or 3 or
             more involved lymph node sites.

          -  Females of childbearing age must be on an acceptable form of birth control per
             institutional standards

          -  Age between 18 and 60

        Exclusion Criteria:

          -  Cardiac ejection fraction ≤ 50%

          -  Hemoglobin-adjusted diffusing capacity for carbon monoxide &lt; 60%

          -  ANC≤1000/μl and Platelets≤75,000/μl

          -  Total bilirubin ≥ 2.0 mg/dl in the absence of a history of Gilbert's disease

          -  Known pregnancy or breast-feeding

          -  Medical illness unrelated to Hodgkin Lymphoma, which, in the opinion of the attending
             physician and/or MSKCC principal investigator, makes participation in this study
             inappropriate.

          -  Peripheral neuropathy &gt; grade 1

          -  Patients receiving treatment with systemic steroids
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Moskowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan-Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Craig Moskowitz, MD</last_name>
    <phone>212-639-2696</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joachim Yahalom, MD</last_name>
    <phone>212-639-5999</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering at Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Moskowitz, MD</last_name>
      <phone>212-639-2696</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center @ Suffolk</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Moskowitz, MD</last_name>
      <phone>212-639-2696</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Moskowitz, MD</last_name>
      <phone>212-639-2696</phone>
    </contact>
    <contact_backup>
      <last_name>Joachim Yahalom, MD</last_name>
      <phone>212-639-5999</phone>
    </contact_backup>
    <investigator>
      <last_name>Craig Moskowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carla Casulo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carla Casulo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering at Mercy Medical Center</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Moskowitz, MD</last_name>
      <phone>212-639-2696</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center</name>
      <address>
        <city>Sleepy Hollow</city>
        <state>New York</state>
        <zip>10591</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Moskowitz, MD</last_name>
      <phone>212-639-2696</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan-Kettering Cancer Center</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 23, 2014</lastchanged_date>
  <firstreceived_date>May 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DACARBAZINE</keyword>
  <keyword>DOXORUBICIN/ADRIAMYCIN</keyword>
  <keyword>SGN-35 (BRENTUXIMAB VEDOTIN)</keyword>
  <keyword>VINBLASTINE</keyword>
  <keyword>Involved-site radiation therapy (ISRT)</keyword>
  <keyword>Early stage</keyword>
  <keyword>13-034</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
